Back to News
Jun 18, 2026 4:00 PM

CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity

CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, CosmoFarm S.A. ("CosmoFarm"), delivered record revenue of over $15 million in the second quarter of 2026, representing an annualized run-rate of over $60 million.

CosmoFarm added more than 80 new pharmacies to its distribution network during the period, continuing the strong customer growth that has made it one of the leading pharmaceutical wholesalers in the greater Athens area.

To support this accelerating growth, Cosmos Health is increasing capital expenditure at CosmoFarm, investing in new robotic automation and artificial intelligence systems to enhance procurement, inventory management, and order fulfillment. The Company is also expanding the size of the CosmoFarm facility to accommodate higher volumes and continued network expansion.

These investments build on CosmoFarm's existing automated infrastructure, including ROWA and SSI SCHÄFER A-frame robotic systems, which have driven improvements in operational efficiency, unit economics, and profitability per customer.

Greg Siokas, CEO of Cosmos Health, stated: "CosmoFarm's record second quarter marks an important milestone, with revenue reaching an annualized run-rate of over $60 million. The addition of over 80 new pharmacies reflects the strength of our distribution platform and the trust of our growing customer base. By investing further in robotic automation, artificial intelligence, and expanded facility capacity, we are positioning CosmoFarm to sustain this momentum, improve margins, and continue scaling profitably."

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed ...